Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Phase 1/2 Recruiting
80 enrolled
MSTH-CAR001
Phase 1/2 Recruiting
30 enrolled
PLYCOM
Phase 1/2 Recruiting
200 enrolled
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
Phase 1/2 Recruiting
30 enrolled
Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
Phase 1/2 Recruiting
50 enrolled
DURGA-3
Phase 1/2 Recruiting
110 enrolled
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Phase 1/2 Recruiting
166 enrolled
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Phase 1/2 Recruiting
130 enrolled
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Phase 1/2 Recruiting
246 enrolled
Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
Phase 1/2 Recruiting
66 enrolled
Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1/2 Recruiting
36 enrolled
SELECT-CAR-NK
Phase 1/2 Recruiting
85 enrolled
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
Phase 1/2 Recruiting
440 enrolled
LINKER-MM1
Phase 1/2 Recruiting
387 enrolled 1 FDA
A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma
Phase 1/2 Recruiting
65 enrolled
LINKER-MM4
Phase 1/2 Recruiting
149 enrolled
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 1/2 Recruiting
62 enrolled
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
Phase 1/2 Recruiting
226 enrolled
DREAMM-20
Phase 1/2 Recruiting
153 enrolled
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
Phase 1/2 Recruiting
70 enrolled
STOMP
Phase 1/2 Recruiting
300 enrolled
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Phase 1/2 Recruiting
250 enrolled
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Phase 1/2 Recruiting
49 enrolled
A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
Phase 1/2 Recruiting
342 enrolled
MELT-MM
Phase 1/2 Recruiting
75 enrolled
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
Phase 1/2 Recruiting
24 enrolled
ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
Phase 1/2 Recruiting
20 enrolled
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
Phase 1/2 Recruiting
37 enrolled
External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease
Phase 1/2 Recruiting
20 enrolled
LINKER-AL2
Phase 1/2 Recruiting
220 enrolled
Study of ODX (OsteoDex) in Multiple Myeloma
Phase 1/2 Recruiting
12 enrolled
Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
Phase 1/2 Recruiting
84 enrolled
A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
Phase 1/2 Recruiting
80 enrolled
The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma
Phase 1/2 Recruiting
20 enrolled
COSTIMM
Phase 1/2 Recruiting
186 enrolled
BAH2573
Phase 1/2 Recruiting
60 enrolled
Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)
Phase 1/2 Recruiting
24 enrolled
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Phase 1/2 Recruiting
128 enrolled
CASSANDRA
Phase 1/2 Recruiting
37 enrolled
ATRA
Phase 1/2 Recruiting
42 enrolled
CAR-T
Phase 1/2 Recruiting
90 enrolled
Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1/2 Recruiting
144 enrolled
BELI(E)VE
Phase 1/2 Recruiting
45 enrolled
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Phase 1/2 Recruiting
80 enrolled
a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Phase 1/2 Recruiting
80 enrolled
Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
Phase 1/2 Recruiting
20 enrolled
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Phase 1/2 Recruiting
116 enrolled
BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
Phase 1/2 Recruiting
10 enrolled
A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1/2 Recruiting
48 enrolled
Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM
Phase 1/2 Recruiting
60 enrolled